Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03837626 · ClinicalTrials.gov registry record · Phase 2
ENAC Blockade and Arterial Stiffness
A Phase 2 study, sponsored by University of Missouri-Columbia.
- Completed
- Registry status
- Phase 2
- Development phase
- 137
- Enrollment target
NCT03837626: Completed Phase 2 study, sponsored by University of Missouri-Columbia.
NCT03837626 is a Phase 2 study that has completed, run by University of Missouri-Columbia. The registered enrollment target is 137 participants, roughly in line with the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03837626, a Phase 2 study, has completed, sponsored by University of Missouri-Columbia.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 137 participants
- Enrollment target
Study Summary
To determine whether treatment with the ENaC inhibitor, amiloride, improves endothelial function and arterial stiffness in obese insulin resistant subjects in a randomized placebo-controlled trial examining pre and postmenopausal women and age-matched men.
Primary Outcome
cfPWV is the gold standard of arterial stiffness. It was assessd during experimental visits, under the same conditions in a blinded manner
Interventions
- DRUG Placebo - Cap
- DRUG Amiloride Pill
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 137 participants |
| Start Date | 2019-07-15 |
| Est. Completion | 2025-04-30 |
| Phase | Phase 2 |
What the finished NCT03837626 record still lists
NCT03837626 is an interventional study that assigns participants to a tested intervention. The registered 137 participants enrollment target is mid-sized for trials with a published cap, roughly in line with the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target.
The record links to 0 conditions, and to 2 interventions - of which Placebo - Cap is the first listed.
NCT03837626 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03837626 about?
NCT03837626 is a clinical study titled "ENAC Blockade and Arterial Stiffness". To determine whether treatment with the ENaC inhibitor, amiloride, improves endothelial function and arterial stiffness in obese insulin resistant subjects in a randomized placebo-controlled trial examining pre and postmenopausal women and age-matched men.
What is the current status of trial NCT03837626?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 137 participants. The study started on 2019-07-15. Estimated completion is 2025-04-30.
What interventions are being tested in trial NCT03837626?
The interventions under investigation include: Placebo - Cap (DRUG), Amiloride Pill (DRUG).
Who is sponsoring clinical trial NCT03837626?
This trial is sponsored by University of Missouri-Columbia, which has 291 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03837626's enrollment target sits among peer trials
137 527th of 2000 higher than 1,474 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05091424 · 137 participants · Phase 1
A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab and a Combined Regimen of Mosunetuzumab and Venetoclax in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia
- NCT05655182 · 137 participants · Phase 1
A Study of BLB-201 RSV Vaccine in Infants and Children
- NCT06571669 · 137 participants · NA
BOOM-IBD2 Pivotal Clinical Trial
- NCT06644768 · 137 participants · Phase 1
A Study of Valemetostat Tosylate Plus Pembrolizumab Versus Pembrolizumab Alone in First-Line NSCLC Without Actionable Genomic Alterations
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI